| CEO: | Adrian Kinkaid |
| Chairman: | Simon Gordon Douglas |
| Chief Scientific Officer: | Richard John Buick |
| Non-Executive Dir: | Colin Walsh, Matthew Baker |
| Address: | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Website: | https://www.fusionantibodies.com/ |
| Sector: | Health Care(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BDQZGK16 |
| Currency | UK Pounds |
| Share Price | 14.50p |
| Change Today | -0.50p |
| % Change | -3.33 % |
| 52 Week High | 19.25p |
| 52 Week Low | 5.80p |
| Volume | 770,644 |
| Shares Issued | 113.66m |
| Market Cap | £16.48m |
| RiskGrade | 464 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:09 | 50,000 @ 14.60p |
| 16:14 | 20,000 @ 14.40p |
| 16:00 | 1,342 @ 14.90p |
| 15:46 | 20,000 @ 14.33p |
| 15:31 | 750 @ 14.30p |
| Chair | Simon Gordon Douglas |
| CEO | Adrian Kinkaid |
You are here: research